Abstract
Recent progress in the field of DNA repair has demonstrated that transient inhibition of DNA damage detection or repair using potent poly(ADP-ribose) polymerase (PARP) inhibitors could improve the efficacy of cancer treatments. Although more study is needed, recent publications lead to optimism that the inhibition of poly(ADP-ribose) synthesis could selectively kill cancer cells when used to treat tumours with defective BRCA proteins. These reports and others shed some light on the DNA damage signalling and repair processes involving PARPs. However, a better understanding of the molecular mechanisms regulated by poly(ADP-ribose) metabolism will be essential before optimism can be replaced by clinical realization.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
DNA Repair / drug effects*
-
Gene Components
-
Heterocyclic Compounds, 4 or More Rings / pharmacology
-
Heterocyclic Compounds, 4 or More Rings / therapeutic use
-
Humans
-
Indoles / pharmacology
-
Indoles / therapeutic use
-
Models, Molecular*
-
Neoplasms / drug therapy*
-
Phenanthrenes / pharmacology
-
Phenanthrenes / therapeutic use
-
Piperazines / pharmacology
-
Piperazines / therapeutic use
-
Poly(ADP-ribose) Polymerase Inhibitors*
-
Poly(ADP-ribose) Polymerases / genetics
-
Quinazolines / pharmacology
-
Quinazolines / therapeutic use
-
Quinazolinones
-
Signal Transduction / drug effects*
-
Signal Transduction / genetics
Substances
-
2-(3-(4-(4-chlorophenyl)-1-piperazinyl) propyl)-4(3H)-quinazolinone
-
CEP-6800
-
Heterocyclic Compounds, 4 or More Rings
-
INO 1001
-
Indoles
-
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride
-
NU 1025
-
Phenanthrenes
-
Piperazines
-
Poly(ADP-ribose) Polymerase Inhibitors
-
Quinazolines
-
Quinazolinones
-
Poly(ADP-ribose) Polymerases